IP Library Granted Patent US 9,610,149
Granted Patent B2
US 9,610,149 · App. 14/831,975 · Granted Apr 4, 2017

Extracellular matrix constructs for treating damaged biological tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,610,149
App. No.
14/831,975
Granted
Apr 4, 2017
Kind
B2
Abstract

Extracellular matrix (ECM) constructs having a biodegradable support scaffold and an anchoring mechanism, which includes a plurality of biodegradable microneedles that are capable of piercing tissue and anchoring therein. In a preferred embodiment, the support scaffold and anchoring mechanism comprise an ECM material. In some embodiments, the microneedles are also capable of administering a biologically active agent and/or a pharmacological composition to the engaged tissue.

Claims (11)

1. An extracellular matrix (ECM) construct for tissue repair, comprising:

a biodegradable and bioremodelable support scaffold; and

a biodegradable and bioremodelable microneedle anchoring member having a top and bottom surface, said microneedle anchoring member including a plurality of biodegradable microneedles that are configured to pierce tissue and anchor therein, said plurality of biodegradable microneedles projecting from at least said microneedle anchoring member top surface,

said biodegradable and bioremodelable support scaffold and anchoring member comprising acellular mesothelial tissue, wherein, when said ECM construct is in communication with host tissue, said microneedle anchoring member secures said ECM construct to said host tissue for an engagement period of time in the range of at least 1-3 months, wherein said ECM construct biodegrades and is at least partially remodeled by said host tissue.

2. The ECM construct of claim 1 , wherein said biodegradable and bioremodelable support scaffold and microneedle anchoring members comprise an integral member.

3. The ECM construct of claim 1 , wherein said acellular mesothelial tissue comprises at least one supplemental biologically active agent.

4. The ECM construct of claim 3 , wherein said supplemental biologically active agent comprises a basic fibroblast growth factor (bFGF).

5. The ECM construct of claim 1 , wherein said acellular mesothelial tissue comprises at least one pharmacological agent.

6. The ECM construct of claim 5 , wherein said pharmacological agent comprises an anti-inflammatory agent.

7. The ECM construct of claim 5 , wherein said pharmacological agent comprises an antibiotic.

8. The ECM construct of claim 5 , wherein said pharmacological agent comprises a statin.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070481/0747 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2016
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 039426/0667 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →